An Emerging Global Leader in the New Generation of Anti-Infective Therapies
Recce Pharmaceuticals Ltd (ASX: RCE) are pioneering a new class of synthetic anti-infectives to address the urgent global health threat posed by superbugs and emerging viral pathogens.
RECCE® 327 and RECCE® 529 have been designed with a unique mechanism of action, with the goal of re-empowering physicians in their potential of an effective treatment that may be used repeatedly against a broad range of bacteria and viruses. RECCE® 529 is a new synthetic polymer formulation with indication against viruses.
Preclinical studies of RECCE® 327 indicates a fast acting, broad-spectrum antibiotic effective against Gram-positive and Gram-negative bacteria, including antibiotic resistant superbugs.
In 2017 RECCE® 327 was awarded Qualified Infectious Disease Product (QIDP) designation under the Generating Antibiotic Initiatives Now (GAIN) Act - labelling RECCE® 327 for Fast Track designation, plus 10 years of market exclusivity post approval.
Recce Pharmaceuticals was founded by Dr. Graham Melrose, a former Executive Director, and Head of Research at Johnson & Johnson Asia Pacific and Australia. Following his discovery of RECCE® 327 and RECCE® 529, Recce Pharmaceuticals has since expanded to include a diverse management team of experts in clinical research and business development who are committed to addressing the urgent global health threat posed by bacterial and viral pathogens.
Recce (pronounced Re-Key) originates from the military term ‘Reconnaissance’ as a military tactic – ‘the aggressive assessment of the disposition of the enemy’. In other words, get troops behind enemy lines, identify the enemy, eliminate the threat, and escape without being noticed.
We have adopted this approach to anti-infectives, where they are designed to:
- Enter the human body,
- Find the infection and threat (deadly bacteria and viruses),
- Eliminate the threat
- Exit without being noticed (side effects)
Our Vision & Values
“To target the global health problem of superbugs”
New synthetic (polymer based) drugs are uniquely used for targeting major human health threats. With over 30 years of polymer experience, Dr Melrose and team are well placed to broaden Recce’s technical capabilities.
Patents are the value of any technology company and Recce Pharmaceuticals Ltd is no exception. With a track record of applying for a patent and it always being accepted, Recce is well positioned to continue expanding its wholly owned international patent portfolio.
As an Australian Stock Exchange (ASX:RCE) listed company, Recce Pharmaceuticals Ltd is funded to pursue its drug development activities, starting with the world’s largest pharmaceutical market the USA – as regulated by the with the U.S. Food and Drug Administration. Recce’s capitalistic culture sees all technical endeavours focused around a commercial outcome.